Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 100Prostatic Neoplasms 62Colorectal Neoplasms 48Nasopharyngeal Carcinoma 45Neoplasms 44Multiple Myeloma 42Stomach Neoplasms 35Neoplasm Metastasis 32Leukemia, Myeloid, Acute 32Ovarian Neoplasms 31Lung Neoplasms 31Carcinoma, Hepatocellular 29Rectal Neoplasms 28Squamous Cell Carcinoma of Head and Neck 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Recurrence 25Small Cell Lung Carcinoma 21Brain Neoplasms 21Esophageal Neoplasms 20Colonic Neoplasms 20Uterine Cervical Neoplasms 19Lymphoma, Large B-Cell, Diffuse 17Head and Neck Neoplasms 17Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Myasthenia Gravis 15

Interventions

eribulin 1Paclitaxel 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × HER2-low Breast Cancer × Clear all
NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
566 enrolled
Breast

HER2-low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡